Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(treprostinil parenteral )
52 results
  • Treprostinil for the treatment of chronic thromboembolic pulmonary hypertension. [Journal Article]
    Expert Rev Respir Med 2019; :1-7Sadushi-Kolici R, Lang IM
  • Introduction: Parenteral treprostinil for patients with pulmonary arterial hypertension has resulted in improvement of exercise capacity, functional class, hemodynamics, and survival. Recently, a first randomized trial performed in patients with chronic thromboembolic pulmonary hypertension confirmed the efficacy of subcutaneous treprostinil in this subset of pulmonary hypertension. Areas covered…
  • Oral treprostinil use in children: a multicenter, observational experience. [Journal Article]
    Pulm Circ 2019 Jul-Sep; 9(3):2045894019862138Kanaan U, Varghese NP, … Ivy DD
  • Pulmonary arterial hypertension is a progressive, incurable disease that occurs in adults and children alike. Therapeutic options for children are limited and infrequently described, including newer agents such as treprostinil, an oral prostanoid. Herein, we describe the pooled pediatric experience in 28 patients from four pediatric pulmonary hypertension programs over two years. This descriptive…
  • Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension. [Journal Article]
    Pulm Circ 2019 Jul-Sep; 9(3):2045894019856471Ivy DD, Feinstein JA, … Hopper RK
  • Treprostinil, a prostacyclin analogue, is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Transition from parenteral to oral treprostinil has been successfully accomplished in adults with PAH but not in children. In this multicenter study, pediatric patients treated with parenteral (Cohort 1) or inhaled (Cohort 2) treprostinil were transitioned to oral treprostinil.…
  • Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. [Journal Article]
    J Heart Lung Transplant 2019; 38(7):748-756Olsson KM, Richter MJ, … Hoeper MM
  • CONCLUSIONS: Risk assessment at 6-12 months after the initiation of add-on intravenous treprostinil in patients with an insufficient response to nonparenteral treatments allows the prediction of transplant-free survival over the ensuing years. Achieving a low-risk profile is associated with excellent outcomes, whereas mortality is high in patients who remain at intermediate or high risk.
  • Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series. [Case Reports]
    Am J Health Syst Pharm 2018; 75(23):1877-1881Fanous SM, Janmohamed M
  • CONCLUSIONS: There is a paucity of published data on how to safely transition patients to oral therapy in the event of complications and problems during parenteral administration of prostacyclins, which can include bloodstream infections, injection-site pain (with use of subcutaneous treprostinil), infusion pump malfunction, and dosing errors due to incorrect dose preparation. This case series describes the transition of 4 patients with World Health Organization (WHO) group I PAH (WHO functional classes II-IV) from i.v. (n = 3) and subcutaneous (n = 1) treprostinil infusion therapy to oral selexipag use. The transition process was completed through the use of 2 cross-titration methods (rapid and slow). A rapid approach was used in 2 cases involving inpatients, with parenteral-to-oral transition completed over 8-13 days; a slow transition method was used in 2 cases, in which outpatients completed the transition over 19-25 weeks. Adverse events during the transitions were headache, nausea, vomiting, diarrhea, and jaw pain.Four patients with WHO group I PAH who were not candidates for continued parenteral treprostinil therapy were safely transitioned to oral selexipag in both inpatient and outpatient settings.
  • Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension. [Case Reports]
    Pulm Circ 2019 Jan-Mar; 9(1):2045894018788846Desole S, Richter MJ, … Ewert R
  • Intravenous prostacyclin-based therapy improves survival in children with pulmonary arterial hypertension (PAH), but is typically administered via an external infusion pump, which places a considerable burden on the patient. Implanted pumps may overcome some of the limitations of external pumps. We describe the first long-term use of an implanted pump for intravenous treprostinil delivery in a pe…
New Search Next